ISIS PHARMACEUTICALS DISCOVERS NEW BINDING TECHNIQUE
ISIS PHARMACEUTICALS DISCOVERS NEW BINDING TECHNIQUE CARLSBAD, Calif., Aug. 31 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIP) has discovered a new method of binding oligonucleotides to RNA, as published in a recent issue of Science, volume 257.
The most important regions of viral or cellular RNA are often highly structured and difficult to bind with antisense oligonucleotides. The Science report describes a new approach, known as pseudo-half-knot formation, in the design of antisense oligonucleotides to target these important structured regions. "Structured regions of RNA represent important targets for antisense drugs, the study of which will better enable us to design such drugs," said Dr. Christopher Mirabelli, senior vice president. Isis has demonstrated the utility of the technique by targeting one of the key regulatory RNA regions of HIV. It was shown that by binding to the HIV RNA using the pseudo-half-knot formation, the viral regulatory protein was displaced from its natural binding site. Isis has filed patent applications on this technique of drug discovery. Isis Pharmaceuticals, Inc., based in northern San Diego County, is engaged in the discovery and development of novel therapeutic products based on antisense oligonucleotides. Isis recently completed its initial Phase I human clinical trials on a new drug, the first antisense drug to be administered to humans, to treat human papillomavirus. -0- 8/31/92 /CONTACT: Christopher Mirabelli, Ph.D., of Isis Pharmaceuticals, Inc., 619-931-9200, or Anthony J. Russo, of Noonan/Russo Communications, 212-979-9180, for Isis Pharmaceuticals/ (ISIP) CO: Isis Pharmaceuticals, Inc. ST: California IN: MTC SU:
TS-LR -- NY011 -- 4815 08/31/92 09:03 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 31, 1992|
|Previous Article:||VISA IS NOT ENTITLED TO STOP CREDIT UNION'S NEW 'MONEYPLUS' CARD|
|Next Article:||WORLDWIDE FOREST PRODUCTS WINS SUPPLY CONTRACT FOR DALLAS LIGHT RAIL SYSTEM|